NCT01764243View on ClinicalTrials.gov

Safety and Efficacy of MT-4666

PHASE2CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

July 31, 2015

Conditions
Alzheimer's Disease
Interventions
DRUG

MT-4666

low dose, high dose

DRUG

Placebo

Trial Locations (1)

Unknown

Kanto

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY